MentionFox
Home › Stakes › 10x Genomics Inc-Class A
5%+ stakes · Schedule 13D and 13G

10x Genomics Inc-Class A: 5%+ holders

Who has reported owning 5% or more of 10x Genomics Inc-Class A, from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

Sell to companies like 10x Genomics Inc-Class A? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · Holder: T. Rowe Price Associates, Inc. · Percent: 11.7% · SCHEDULE 13G
  • · Holder: ARK Investment Management LLC · Percent: 8.56% · SCHEDULE 13G/A
  • · Holder: Vanguard Capital Management · Percent: 5.24% · SCHEDULE 13G
  • · Holder: Vanguard Portfolio Management · Percent: 5.93% · SCHEDULE 13G
  • · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
At 5% or more6
Filings19
Latest filing2026-09-08

10x Genomics Inc-Class A has 19 Schedule 13D or 13G filings on record since 2025-07-16. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Fmr LLC15.6%18,543,562SCHEDULE 13G/A, 2026-03-062026-02-27
T. Rowe Price Associates, Inc.11.7%14,044,020SCHEDULE 13G, 2026-09-082026-08-31
ARK Investment Management LLC8.56%10,003,058SCHEDULE 13G/A, 2026-08-142026-06-30
BlackRock, Inc.7.6%8,496,636SCHEDULE 13G/A, 2025-07-162025-06-30
Vanguard Portfolio Management5.93%6,981,683SCHEDULE 13G, 2026-04-282026-03-31
Vanguard Capital Management5.24%6,166,597SCHEDULE 13G, 2026-04-292026-03-31
Sumitomo Mitsui Trust Group, Inc.4.7%5,381,219SCHEDULE 13G/A, 2025-10-272025-09-30
Amova Asset Management Americas, Inc.4.7%5,376,883SCHEDULE 13G/A, 2025-11-132025-09-30
Millennium Management LLC2.7%3,060,859SCHEDULE 13G/A, 2025-08-122025-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-252026-03-13

Holding shares or following this stake? See who's behind 10x Genomics Inc-Class A and the warning signs.

Watch 10x Genomics Inc-Class A: email me the next time it files something

Free to see. No signup.

Want the whole picture on 10x Genomics Inc-Class A?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on 10x Genomics Inc-Class A: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on 10x Genomics Inc-Class A covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    19 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledHolderPercentFiling
2025-07-16BlackRock, Inc.7.6%SCHEDULE 13G/A
2025-07-31Sumitomo Mitsui Trust Group, Inc.5.4%SCHEDULE 13G
2025-08-06Fmr LLC8.8%SCHEDULE 13G/A
2025-08-07Fmr LLC10.3%SCHEDULE 13G/A
2025-08-12Millennium Management LLC2.7%SCHEDULE 13G/A
2025-08-13Nikko Asset Management Americas, Inc.5.4%SCHEDULE 13G
2025-10-27Sumitomo Mitsui Trust Group, Inc.4.7%SCHEDULE 13G/A
2025-10-30The Vanguard Group11.6%SCHEDULE 13G/A
2025-11-04ARK Investment Management LLC10.39%SCHEDULE 13G/A
2025-11-05Fmr LLC8.1%SCHEDULE 13G/A
2025-11-13Amova Asset Management Americas, Inc.4.7%SCHEDULE 13G/A
2026-01-08Fmr LLC10.8%SCHEDULE 13G/A
2026-03-06Fmr LLC15.6%SCHEDULE 13G/A
2026-03-24The Vanguard Group0%SCHEDULE 13G/A
2026-03-25The Vanguard Group0%SCHEDULE 13G/A
2026-04-28Vanguard Portfolio Management5.93%SCHEDULE 13G
2026-04-29Vanguard Capital Management5.24%SCHEDULE 13G
2026-08-14ARK Investment Management LLC8.56%SCHEDULE 13G/A
2026-09-08T. Rowe Price Associates, Inc.11.7%SCHEDULE 13G
RSS

Tools for this story

Each opens in a new tab, filled in for 10x Genomics Inc-Class A. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes

Cite this page

Permanent URL: https://mentionfox.com/stakes/10x-genomics-inc-class-a
Last updated 2026-10-07
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
10x Genomics Inc-Class A 5%+ holders: 6 at 5% or more, largest Fmr LLC 15.6%. MentionFox, 2026-10-07. https://mentionfox.com/stakes/10x-genomics-inc-class-a